"JPMorgan doctor survey confirms long-term potential of Ingrezza
"JPMorgan analyst Anupam Rama says his survey of 25 U.S. physicians confirm the long-term potential of Neurocrine Biosciences' Ingrezza. There is "plenty of room" to continue to penetrate the tardive dyskinesia market and Neurocrine's Ingrezza market share is expected to grow, Rama tells investors in a research note. That said, near-term Ingrezza market dynamics due to the ongoing COVID-19 pandemic are still uncertain, says Rama. He keeps a Neutral rating on Neurocrine shares with a $124 price target."